365 related articles for article (PubMed ID: 30347770)
21. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
Machulkin AE; Shafikov RR; Uspenskaya AA; Petrov SA; Ber AP; Skvortsov DA; Nimenko EA; Zyk NU; Smirnova GB; Pokrovsky VS; Abakumov MA; Saltykova IV; Akhmirov RT; Garanina AS; Polshakov VI; Saveliev OY; Ivanenkov YA; Aladinskaya AV; Finko AV; Yamansarov EU; Krasnovskaya OO; Erofeev AS; Gorelkin PV; Dontsova OA; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
J Med Chem; 2021 Apr; 64(8):4532-4552. PubMed ID: 33822606
[TBL] [Abstract][Full Text] [Related]
23. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
Akinboye ES; Rosen MD; Bakare O; Denmeade SR
Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
[TBL] [Abstract][Full Text] [Related]
24. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
25. Redox sensitive lipid-camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery.
Du Y; Ling L; Ismail M; He W; Xia Q; Zhou W; Yao C; Li X
Int J Pharm; 2018 Oct; 549(1-2):352-362. PubMed ID: 30099214
[TBL] [Abstract][Full Text] [Related]
26. The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin.
Lu J; Liu C; Wang P; Ghazwani M; Xu J; Huang Y; Ma X; Zhang P; Li S
Biomaterials; 2015 Sep; 62():176-87. PubMed ID: 26057133
[TBL] [Abstract][Full Text] [Related]
27. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and biological evaluation of novel pyrenyl derivatives as anticancer agents.
Bandyopadhyay D; Sanchez JL; Guerrero AM; Chang FM; Granados JC; Short JD; Banik BK
Eur J Med Chem; 2015 Jan; 89():851-62. PubMed ID: 25462285
[TBL] [Abstract][Full Text] [Related]
30. Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Leamon CP; Reddy JA; Bloomfield A; Dorton R; Nelson M; Vetzel M; Kleindl P; Hahn S; Wang K; Vlahov IR
Bioconjug Chem; 2019 Jun; 30(6):1805-1813. PubMed ID: 31075200
[TBL] [Abstract][Full Text] [Related]
31. Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
Guo Z; Lai Y; Du T; Zhang Y; Chen J; Bi L; Lin T; Liu H; Wang W; Xu K; Jiang C; Han J; Zhang C; Dong W; Huang J; Huang H
Chin Med J (Engl); 2014; 127(5):929-36. PubMed ID: 24571890
[TBL] [Abstract][Full Text] [Related]
32. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
Minelli R; Cavalli R; Ellis L; Pettazzoni P; Trotta F; Ciamporcero E; Barrera G; Fantozzi R; Dianzani C; Pili R
Eur J Pharm Sci; 2012 Nov; 47(4):686-94. PubMed ID: 22917641
[TBL] [Abstract][Full Text] [Related]
33. Co-delivery of 10-hydroxycamptothecin with doxorubicin conjugated prodrugs for enhanced anticancer efficacy.
Zhang Y; Xiao C; Li M; Chen J; Ding J; He C; Zhuang X; Chen X
Macromol Biosci; 2013 May; 13(5):584-94. PubMed ID: 23420692
[TBL] [Abstract][Full Text] [Related]
34. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
35. Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity.
Zhang Z; Tanabe K; Hatta H; Nishimoto S
Org Biomol Chem; 2005 May; 3(10):1905-10. PubMed ID: 15889173
[TBL] [Abstract][Full Text] [Related]
36. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Evaluation of
Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
[TBL] [Abstract][Full Text] [Related]
38. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
Foss CA; Mease RC; Fan H; Wang Y; Ravert HT; Dannals RF; Olszewski RT; Heston WD; Kozikowski AP; Pomper MG
Clin Cancer Res; 2005 Jun; 11(11):4022-8. PubMed ID: 15930336
[TBL] [Abstract][Full Text] [Related]
39. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
40. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]